Biohaven Ltd. (BHVN) surged on positive data from a pivotal study evaluating its drug candidate, troriluzole, for treating spinocerebellar ataxia (SCA). The study demonstrated the drug’s ability to slow disease progression, prompting Biohaven to file for FDA approval in late 2024. This breakthrough could provide much-needed hope for patients battling this debilitating condition.
Biohaven Ltd. (BHVN) announced positive results from a pivotal study demonstrating the efficacy of troriluzole in slowing the progression of Spinocerebellar Ataxia (SCA). The drug showed statistically significant improvements in f-SARA scores after three years, leading to a potential FDA approval and commercialization in 2025.
The Dow Jones Industrial Average closed lower on Friday, but some stocks saw significant gains, notably Biohaven Ltd. after positive trial results for its spinocerebellar ataxia treatment. Other notable gainers included BitFuFu, TeraWulf, and Gevo.
